Invitation to Year End 2015 Conference Call of MorphoSys AG on March 2, 2016

MARTINSRIED / MUNICH, Germany, Feb. 25, 2016 -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) will publish its Annual Financial Results 2015 on March 2, 2016 at 7:00 a.m. CET.

The Management team of MorphoSys AG will host a conference call and webcast to present MorphoSys's Annual Financial Results 2015 and provide an outlook for 2016.

Date:   Wednesday, March 2, 2016
Time:   02:00 p.m. CET (01:00 p.m. GMT, 08:00 a.m. EST)

Dial-in numbers (listen only):
Germany: +49 89 2444 32975
United Kingdom: +44 20 3003 2666
USA:   +1 202 204 1514
 
Participants of the call will be:
Dr. Simon Moroney, Chief Executive Officer
Jens Holstein, Chief Financial Officer
Dr. Arndt Schottelius, Chief Development Officer
Dr. Marlies Sproll, Chief Scientific Officer

We request that you please dial in up to 10 minutes before the call to ensure a prompt start and a secure line.

The presentation slides and webcast link will be available at the Company's website at www.morphosys.com/conference-calls

A slide-synchronized audio replay of the conference will also be available at the corporate website following the live event.

About MorphoSys:

MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare.

Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com.

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia®, 100 billion high potentials®, Slonomics®, Lanthio Pharma® and LanthioPep® are registered trademarks of the MorphoSys Group.

This communication contains certain forward-looking statements concerning the MorphoSys group of companies, The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties, Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated, MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned

For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR

Alexandra Goller
Senior Manager Corporate Communications & IR

Jochen Orlowski
Associate Director Corporate Communications & IR

Tel: +49 (0) 89 / 899 27-404
[email protected]

YE 2015 Conference Call Alert http://hugin.info/130295/R/1988883/730410.pdf

HUG#1988883